Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1FGFR1 Gene Amplification 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Cisplatin 33Radiotherapy 23Cetuximab 18Paclitaxel 14Docetaxel 14pembrolizumab 13Carboplatin 12Fluorouracil 10Radiotherapy, Intensity-Modulated 8Nivolumab 8Drug Therapy 7Erlotinib Hydrochloride 6Panitumumab 5dacomitinib 4Radiation 4Methotrexate 4Esophagectomy 4130-nm albumin-bound paclitaxel 4durvalumab 3ON 01910 3Leucovorin 3Gemcitabine 3Chemoradiotherapy 3vandetanib 2palbociclib 2osimertinib 2nedaplatin 2fludarabine 2cabazitaxel 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Squamous Cell × AZD4547 × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡